Checkpoint Therapeutics, Inc. is a commercial-stage immunotherapy and targeted oncology company focused on the acquisition, development and commercialization of novel treatments for patients with solid tumor cancers. Its product candidates include UNLOXCYTTM (cosibelimab-ipdl) for the treatment of adults with metastatic cSCC or locally advanced cSCC who are not candidates for curative surgery or curative radiation. Additionally, the Company is engaged in evaluating its lead investigational small-molecule, targeted anti-cancer agent, olafertinib, a third-generation epidermal growth factor receptor (EGFR) inhibitor, as a potential new treatment for patients with EGFR mutation-positive non-small cell lung cancer.

Employees

Sector

Biotechnology & Medical Research

More about the company

Income Statement and Estimates

More financial data

Market Closed - Nasdaq 04:00:00 2025-05-29 pm EDT			5-day change	1st Jan Change
4.260 ^USD	+0.71%		-.--%	-

25-06-01	Checkpoint Therapeutics, Inc.(NasdaqCM:CKPT) dropped from S&P TMI Index	CI
25-05-30	Sun Pharmaceutical Industries Limited completed the acquisition of Checkpoint Therapeutics, Inc. from Fortress Biotech, Inc., Armistice Capital Master Fund Ltd., managed by Armistice Capital LLC and others.	CI

Market Cap	371M 320M 301M 274M 515M 35.52B 523M 3.53B 1.38B 17.76B 1.39B 1.36B 59.17B	P/E 2023	-1.23x	P/E 2024	-2.26x
Enterprise Value	364M 314M 296M 269M 506M 34.89B 513M 3.47B 1.36B 17.45B 1.37B 1.34B 58.12B	EV / Sales 2023	475x	EV / Sales 2024	3,650x
Free-Float	47.41%	Yield 2023 *	-	Yield 2024	-

25-06-01	Checkpoint Therapeutics, Inc.(NasdaqCM:CKPT) dropped from S&P TMI Index	CI
25-05-30	Sun Pharmaceutical Industries Limited completed the acquisition of Checkpoint Therapeutics, Inc. from Fortress Biotech, Inc., Armistice Capital Master Fund Ltd., managed by Armistice Capital LLC and others.	CI
25-05-30	Sun Pharmaceutical Industries Completes Acquisition Of Checkpoint Therapeutics	RE
25-05-30	Fortress Biotech Closes Sale of Checkpoint Therapeutics Unit	MT
25-05-30	Checkpoint Therapeutics, Inc. Appoints Zvi Albert as Chief Financial Officer	CI
25-05-30	Checkpoint Therapeutics, Inc. Announces Board and Executive Changes	CI
25-05-29	Checkpoint Therapeutics, Inc.(NasdaqGM:CKPT) dropped from NASDAQ Composite Index	CI
25-05-13	Checkpoint Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
25-03-28	Checkpoint Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2024	CI
25-03-27	Checkpoint Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt	CI
25-03-11	HC Wainwright Downgrades Checkpoint Therapeutics to Neutral From Buy, $20 Price Target	MT
25-03-10	Lake Street Downgrades Checkpoint Therapeutics to Hold From Buy, $4.10 Price Target	MT
25-03-10	Checkpoint Therapeutics to Be Acquired by India's Sun Pharmaceutical -- Checkpoint Shares Jump Monday	MT

25-03-11	HC Wainwright Downgrades Checkpoint Therapeutics to Neutral From Buy, $20 Price Target	MT
25-03-10	Lake Street Downgrades Checkpoint Therapeutics to Hold From Buy, $4.10 Price Target	MT
23-12-20	B. Riley Lowers Checkpoint Therapeutics' Price Target to $4 From $8, Keeps Buy Rating	MT
23-08-22	B. Riley Lowers Checkpoint Therapeutics' Price Target to $8 From $15, Keeps Buy Rating	MT
23-08-15	Lake Street Adjusts Checkpoint Therapeutics Price Target to $14 From $16, Maintains Buy Rating	MT

Checkpoint Therapeutics, Inc. Stock

Stocks

CKPT

US1628282063

Biotechnology & Medical Research

Valuation: Checkpoint Therapeutics, Inc.

Latest news : Checkpoint Therapeutics, Inc.

Analysts' recommendations: Checkpoint Therapeutics, Inc.

Press Releases: Checkpoint Therapeutics, Inc.

News in other languages: Checkpoint Therapeutics, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Checkpoint Therapeutics, Inc.

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

Income Statement and Estimates

25-05-30	Fortress Biotech Announces Closing of Sale of Subsidiary Checkpoint Therapeutics	AQ
25-05-13	Checkpoint Therapeutics Reports First Quarter Financial Results and Recent Corporate Updates	AQ
25-04-29	CHECKPOINT INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Checkpoint Therapeutics, Inc. - CKPT	BU
25-03-28	Checkpoint Therapeutics Reports Full-Year 2024 Financial Results and Recent Corporate Updates	AQ
25-03-14	CHECKPOINT INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Checkpoint Therapeutics, Inc. - CKPT	BU

24-08-22	Avery Dennison Corporation : Todo lo que busca
24-07-18	Zscaler, Inc.: de kunst van de Zero Trust-aanpak
24-07-17	Zscaler: l'arte dell'approccio zero trust
24-07-16	Zscaler, Inc.: El arte del enfoque de confianza cero
24-07-16	Zscaler : l'art de l'approche zero trust

Date	Insider	Type	Main position	Quantity	% Market Cap.
5/30/25	James Oliviero	Tender	Chief Executive Officer	3,759,929	7.8116%
5/30/25	William Gray	Tender	Chief Financial Officer	1,446,322	3.0049%
5/29/25	FORTRESS BIOTECH, INC.	Issuer sale	Company	700,000	7.5395%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
CHECKPOINT THERAPEUTICS, INC.	+0.71%	-.--%	-.--%	+91.89%	357M
WUXI APPTEC CO., LTD.	+0.17%	+4.35%	+72.39%	+114.97%	73.45B
ARGENX SE	+0.53%	+14.98%	+56.53%	+91.84%	62.99B
INSMED INCORPORATED	+0.11%	-3.10%	+0.94%	+491.16%	28.05B
WUXI BIOLOGICS (CAYMAN) INC.	-1.40%	+4.81%	+60.85%	+20.35%	25.42B
BIONTECH SE	+1.26%	-0.05%	-17.59%	-15.96%	23.3B
GENMAB A/S	+0.95%	+4.27%	+40.15%	-14.87%	19.45B
PHARMAESSENTIA CORPORATION	-0.71%	-4.11%	+243.99%	+423.83%	18.16B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	-3.50%	-0.95%	+14.80%	+515.88%	16.53B
EXELIXIS, INC.	+1.53%	+3.49%	+40.68%	+151.75%	13.16B
Average	-0.03%	+3.27%	+51.27%	+187.09%	28.09B
Weighted average by Cap.	+0.05%	+5.68%	+57.08%	+164.20%

	2023	2024
Net sales	103K 88.96K 83.7K 76.07K 143K 9.87M 145K 982K 385K 4.94M 387K 378K 16.44M	41K 35.41K 33.32K 30.28K 56.95K 3.93M 57.79K 391K 153K 1.96M 154K 151K 6.54M
Net income	-51.85M -44.78M -42.13M -38.29M -72.02M -4.97B -73.08M -494M -194M -2.48B -195M -190M -8.28B	-56.24M -48.57M -45.7M -41.54M -78.13M -5.39B -79.27M -536M -210M -2.7B -211M -207M -8.98B
Net Debt	-4.93M -4.26M -4M -3.64M -6.85M -472M -6.95M -46.98M -18.41M -236M -18.5M -18.1M -787M	-6.6M -5.7M -5.37M -4.88M -9.17M -633M -9.31M -62.95M -24.67M -316M -24.79M -24.26M -1.05B

3 years	1.3	4.5
5 years	1.3	46.4
10 years	1.3	150